Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Brivaracetam products are in shortage in Canada (1 of 8 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
An antiseizure medication used to treat epilepsy.
Products affected
1 / 8
In shortage since
Jan 6, 2026
Reports on file
13
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
APO-BRIVARACETAM
25MG · TABLET · APOTEX INC
DIN 02538687 · since Jan 6, 2026, est. end Apr 3, 2026 · Disruption of the manufacture of the drug.
Resolved
APO-BRIVARACETAM
100MG · TABLET · APOTEX INC
DIN 02538717 · ended Apr 2, 2026 · Disruption of the manufacture of the drug.
Resolved
APO-BRIVARACETAM
50MG · TABLET · APOTEX INC
DIN 02538695 · ended Apr 2, 2026 · Disruption of the manufacture of the drug.
Resolved
APO-BRIVARACETAM
75MG · TABLET · APOTEX INC
DIN 02538709 · ended Mar 12, 2026 · Disruption of the manufacture of the drug.
Resolved
APO-BRIVARACETAM
75MG · TABLET · APOTEX INC
DIN 02538709 · ended Feb 13, 2025 · Disruption of the manufacture of the drug.
Resolved
APO-BRIVARACETAM
50MG · TABLET · APOTEX INC
DIN 02538695 · ended Feb 13, 2025 · Disruption of the manufacture of the drug.
Resolved
BRIVLERA
10MG · SOLUTION · UCB CANADA INC
DIN 02452987 · ended Jun 12, 2024 · Demand increase for the drug.
Resolved
BRIVLERA
10MG · SOLUTION · UCB CANADA INC
DIN 02452987 · ended Jan 18, 2022 · Demand increase for the drug.
Resolved
BRIVLERA
10MG · SOLUTION · UCB CANADA INC
DIN 02452987 · ended Nov 5, 2021 · Demand increase for the drug.
Resolved
BRIVLERA
10MG · SOLUTION · UCB CANADA INC
DIN 02452987 · ended Jan 15, 2021 · Delay in shipping of the drug.
Resolved
BRIVLERA
25MG · TABLET · UCB CANADA INC
DIN 02452944 · ended Jun 8, 2020 · Delay in shipping of the drug.
Resolved
BRIVLERA
10MG · TABLET · UCB CANADA INC
DIN 02452936 · ended Jun 2, 2020 · Delay in shipping of the drug.
Showing 12 of 13 reports. All reports are on file with Health Canada.
What's happening
Brivaracetam is currently affected by an active shortage report filed with Health Canada by APOTEX INC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Brivaracetam is classified under “ANTIEPILEPTICS” (ATC N03AX).
Recent changes
No changes recorded yet.
Common questions
What is Brivaracetam used for?
An antiseizure medication used to treat epilepsy.
When will Brivaracetam be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Brivaracetam in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Possible alternatives in the same class (antiepileptics)
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.